RISE
An Italian Registry for Infection Surveillance of Patients Undergoing Salvage Treatment With Elranatamab Monotherapy
Sponsor study identifier
observational
50
0 countries
N/A
Study Start
August 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The primary objective of this study is to measure the infection rate and presentation pattern in first 12 months of therapy with elranatamab as standard clinical practice in adult patients with Relapsed/Refractory Multiple Myeloma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 27, 2026
Actual (reported)May 4, 2026
Actual (reported)August 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Infection rate in the first 12 months of therapy with elranatamab
12 months
Adult patients with Relapsed/Refractory Multiple Myeloma treated with elranatamab as standard clinical practice
First Submitted
April 27, 2026
First Posted
May 4, 2026
Study Start
August 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
February 2028
EstimatedReal-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 4, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: